No abstract

Objectives Swelling, pain and trismus after the surgical removal of the mandibular third molars are the most common and expected postoperative complications. The aim of this cross-sectional study was to assess the association of those postoperative complications and BMI after surgical removal of the mandibular third molars. Material and methods 84 patients who required the surgical removal of their lower third molar were enrolled in this study and were divided into 4 groups dependent on their BMI. Data were tested by one-way analysis of variance (Welch's ANOVA). The differences were tested by the intragroup using the Games-Howell test. Results The effect of BMI on pain had a statistically significant difference within the first 24 postoperative hours: 4 hours (p=0.014), 6 hours (p=0.034, p=0.049), 12 hours (p= 0.00.P=0.023), and 24 hours (p=0.010). For swelling and trismus in the exception on first postoperative day between underweight and normal weight groups (p=0.026), and underweight and overweight groups (p=0.014) no statistically significant correlation was found Conclusion BMI has an impact on a patient’s early postoperative recovery

No abstract

This is the first case report where two patients were under uniform denosumab administration protocol in diffuse sclerosing osteomyelitis (DSO) treatment and were closely monitored for 18 months. Objectives: This study aimed to describe the beneficial effects of denosumab in DSO treatment as well as pain relief and the significant lack of long-term use due to poorer outcomes after repeated use. DSO of the jaw is a poorly understood rare chronic disease the treatment of which is still very challenging despite a rapid development of medicine. Different medical treatments have been proposed without any significant long-lasting success. Bisphosphonates have offered substantial clinical benefit in DSO therapy, but due to harmful pharmacodynamic properties, denosumab therapy has been used to replace bisphosphonate therapy. Patients had a reduction in pain intensity with each subsequent application of denosumab but with less success than the first administration of denosumab. This case report has shown that denosumab could be a promising conservative treatment option for pain treatment in patients suffering from DSO.

The extrapulmonary manifestations of Coronavirus Disease 2019 (COVID-19) are common. However, radiological reports presenting urinary tract abnormalities related to COVID-19 were not widely published. We present a case of a female patient with a mild course of the COVID-19 disease, which affected the entire urinary tract. CT scanning showed inflammatory kidney changes with multiple ureter and bladder blood clots accompanied by a decrease in renal function. A literature review found only several publications that included imaging of urinary tract manifestations of COVID-19, generally presenting as renal infarctions due to a COVID-19 related hypercoagulability state. Also, there is evidence of some discrete changes in renal parenchymal CT attenuation values due to kidney inflammation in COVID-19 patients. However, imaging of other parts of the urinary system, with the exception of the kidneys, are rarely described to be affected by COVID-19. More clinical attention is needed to diagnose the unknown aspects of the disease.